جستجوی مقالات مرتبط با کلیدواژه « tissue transglutaminase » در نشریات گروه « پزشکی »

The present study aims to determine the rate of mucosal recovery and predictors of persistent mucosal damage after gluten free diet (GFD).

Celiac disease (CD) is a complex multi-systemic autoimmune disease triggered by exposure to dietary gluten in genetically predisposed individuals. There is still little evidence on the best method for assessing GFD adherence and mucosal recovery during treatment.

The retrospective study included only adult patients (age≥18 years old), with biopsy-proven CD evaluated at a tertiary referral centre between 2016 and 2021. We performed a logistic regression analysis to identify factors associated with partial mucosal recovery (MR) after GFD. We included in the multivariate analysis parameters available at the time of CD diagnosis.

A total of 102 patients were enrolled, two thirds were females, median age of 39 years (yrs). The initial biopsy analysis showed different stages of villous atrophy (VA) in 79 (77.4%) cases, while in 23(22.5%) cases showed mild enteropathy (Marsh 1, 2). After at least 12 months of GFD, 26 (25.5%) patients had persistent VA despite good or excellent adherence to GFD. Younger patients (< 35yrs), who showed severe mucosal damage (Marsh 3c lesions) and who had increased anti-gliadin antibody (AGA) levels were at risk for failure to obtain mucosal recovery (MR). Logistic regression analysis demonstrated that complete mucosal atrophy (P=0.007) and high AGA antibody levels (cutoff 129 U/ml, P=0.001) were independent risk factors for lack of mucosal improvement after at least 12 months of GFD. Interestingly, genotype, tTG-IgA antibody levels, or duration of GFD levels did not influence the occurrence of MR.

Although AGA seropositivity has lost much of their diagnostic significance in recent years due to the introduction of the more sensitive and specific antibody tests, our study reported that patients aged < 35 yrs, who showed severe mucosal damage (Marsh 3c lesions) and who had increased AGA antibody levels at diagnosis were at risk for failure to obtain MR. The elevated AGA levels at diagnosis could be used as a prognostic tool for assessing MR.

Celiac disease (CeD) is a chronic inflammatory small intestine disorder caused by an abnormal immune response to an array of the epitopes of the wheat gluten and related proteins of rye and barley in genetically susceptible individuals. Midkine (MK) is an angiogenic cytokine, chemotactic in the direction of polymorphonuclear neutrophils and macrophages, and a T‑regulatory cell suppressor. So far, a possible relationship with CeD has not yet been explored. Diagnosis of CeD is based on serologic test in a clinical setting suggestive of CeD and confirmatory histologic examination of the duodenal biopsy. Sometimes, genetic testing of human leukocyte antigen (HLA)‑DQ2 and HLA‑DQ8 may be needed. The objective of this study was to measure and compare the circulating MK in the celiac patients and healthy individuals.

Twenty newly untreated CeD cases and 20 normal controls were enrolled in this study. The enzyme‑linked immunosorbent assay was used to measure the circulating MK in the celiac patients and controls.

There was insignificant difference in the circulating MK between the patients and controls (P > 0.05).

The study results suggest that the MK marker does not have any diagnostic value in CeD activity to be used at the time of diagnosis or during follow‑ups.

Mycobacterium tuberculosis (TB) is a widespread life-threatening infection worldwide. There is an uncertainty in the association between the emergence of autoimmune antibodies and TB.

We hereby aimed to screen anti-tissue transglutaminase (anti-tTG) IgA in patients with TB in an Iranian population.

This was a cross sectional study conducted on smear positive TB patients admitted to the Respiratory Diseases Management Center of the city of Zabol, Sistan and Baluchestan Province of Iran during 2017 - 2018. Anti-tTG IgA level was determined using an ELISA kit (Pars Azmoun, Iran). Statistical analyses were performed in SPSS 19 software.

Overall, 162 patients were evaluated. Females and males constituted 87 (53.7%) and 75 (46.3%) of the patients respectively. The mean age was 51.7 ± 22.3 years (range of 1 - 83). Afghan patients constituted 16 (9.9%) and the remaining were Iranians. The therapy course was successfully completed in 78 (48.1%) patients, and 67 (41.4%) improved following treatments. Overall, 5 patients had active TB with 2 drug-resistant cases. Pulmonary tuberculosis was diagnosed in 127 (78.4%) while 35 (21.6%) had extra-pulmonary disease. The mean titer of anti-tTG IgA was 22.59 ± 107.7 (range of 0.8 - 940). Overall, 19 (11.9%) of the patients showed elevated levels of the antibody. There was no significant association between anti-tTG IgA titer with neither demographic nor clinical variables.

Although anti-tTG IgA antibody test was positive in a relatively high ratio of our patients with TB, the clinical implications of this phenomenon were not significant.

Mycobacterium tuberculosis (TB) is a widespread life-threatening infection worldwide. There is an uncertainty in the association between the emergence of autoimmune antibodies and TB.

We hereby aimed to screen anti-tissue transglutaminase (anti-tTG) IgA in patients with TB in an Iranian population.

This was a cross sectional study conducted on smear positive TB patients admitted to the Respiratory Diseases Management Center of the city of Zabol, Sistan and Baluchestan Province of Iran during 2017 - 2018. Anti-tTG IgA level was determined using an ELISA kit (Pars Azmoun, Iran). Statistical analyses were performed in SPSS 19 software.

Overall, 162 patients were evaluated. Females and males constituted 87 (53.7%) and 75 (46.3%) of the patients respectively. The mean age was 51.7 ± 22.3 years (range of 1 - 83). Afghan patients constituted 16 (9.9%) and the remaining were Iranians. The therapy course was successfully completed in 78 (48.1%) patients, and 67 (41.4%) improved following treatments. Overall, 5 patients had active TB with 2 drug-resistant cases. Pulmonary tuberculosis was diagnosed in 127 (78.4%) while 35 (21.6%) had extra-pulmonary disease. The mean titer of anti-tTG IgA was 22.59 ± 107.7 (range of 0.8 - 940). Overall, 19 (11.9%) of the patients showed elevated levels of the antibody. There was no significant association between anti-tTG IgA titer with neither demographic nor clinical variables.

Although anti-tTG IgA antibody test was positive in a relatively high ratio of our patients with TB, the clinical implications of this phenomenon were not significant

The development of highly performing serological tests to identify patients with coeliac disease (CD), allowed large scale screening studies to be carried out and the results transformed our understanding of the prevalence of the condition in the general population. The next logical step was to ask whether CD could be reliably diagnosed by these tests without the need for small intestinal biopsies. This was shown to be the case. Studies from Derby, UK, indicated that about half of adult patients can be diagnosed in this way and similar figures have been provided for children. When considering this approach, it is essential that laboratories only use highly performing test kits that they have validated to measure tissue transglutaminase antibodies because all kits do not function to the same high standard. There remains a place for biopsy when criteria for serological diagnosis are not met, if the diagnosis of CD is strongly suspected but serological tests are negative or in patients not showing the expected responses to gluten free diet or otherwise causing concern, when not only small bowel biopsy will be indicated but also other investigations. Those with refractory CD should not be compromised by this diagnostic strategy. As serological tests become more refined and information accumulates, it is likely that this mode of diagnosis will gather momentum for the benefit of patients and carers. This brief review looks at the evidence for making the diagnosis of CD in some cases by serological tests alone.

We are extremely grateful for the communication of acceptance received regarding the letter to the editor dated 03.06.2017. Please find attached the revised letter to the editor as per the recommended suggestions.
In a brief report on “Correlation between cut-off level of tissue transglutaminase antibody and Marsh classification” published in October 2016 by Azita Ganji et al, the role of Immunoglobulin A- tissue transglutaminase (IgA- tTG) has been adequately explained. However, certain discrepancies have been noticed.

Celiac disease (CD) is an auto-immune disorder. The prevalence of CD has been estimated mainly based on serological tests. The aim of this study was to evaluate the seroprevalence of celiac disease in the adult general population of Mashhad, northeast of Iran and pitfall of serology in epidemiological studies considering the importance of serology titer.
1558 subjects aged 35 to 65 years and 1025 individuals aged between 15 to 35 years were selected randomly from multistage cluster sampling papulation for this cross sectional study. Anti-tissue transglutaminase (tTG)-IgA assay was performed by ELISA(Enzyme-Linked Immunosorbent Assay). The manufacture’s cut-off point of anti tTG was 20 IU/mL and the prevalence of positive serology was estimated based on being just above the upper limit of normal (20 IU/mL), twice or three times above the normal value at 40 and 60 IU/mL, respectively.
In both age group 35-65 year-old and 15 to 35 years adults, the prevalence of positive serology was 1.2% for anti-tTG level more than 60 IU/mL, which was three times of the kit references (95% CI: 0.7- 1.9) and (95% CI: 0.7-2.1), and based on our previous study in Mashhad if we consider the cut-off point as 76 IU/mL anti–tTG for mucosal atrophy, the prevalence of CD would be 0.69.
Epidemiological data of CD is mainly based on serology and as these tests are to some extent non-specific at lower levels, the accuracy of the previous reported prevalence of CD in some studies are questionable and level of anti-tTG is important.

It is suggested that constipation could be due to celiac disease (CD); therefore, this study aimed to determine the prevalence of positive tissue transglutaminase (tTG) IgA test among children with functional constipation (FC).
In this case-control study, 182 consecutive patients with FC who fulfilled the Rome III criteria as cases were compared with 240 healthy children as the control group in terms of suspicious CD by measuring the serum tTG IgA level.
There was a significant difference in favor of the case group in terms of serum tTG IgA levels (P = 0.000). The probability of having CD would change based on belonging to each group (case/control odds ratio [OR] = 0.222).
With respect to these data, tTG IgA level was observed to be significantly higher in patients relative to healthy children; therefore, it is recommended that patients be screened for CD through the tTG IgA.

Celiac disease is an autoimmune mediated small intestine inflammation which is occurred due to hypersensitivity reaction to gluten and related proteins in diet in genetically predisposing individuals. Prevalence of celiac among the population is about 0.5 – 1 % in most countries. Frequency of celiac disease in children is a subject of few research. In this study, we aim to determine the frequency of celiac disease in patients presenting with functional constipation.This cross-sectional one which was conducted on children referring to Imam Reza Clinic, affiliated to Shiraz University of Medical Sciences during one year starting from 2011, March 20. One hundred and one children 2-18 years of age which all had constipation for more than 2 months according to ROME III criteria. The entire participants underwent serologic studies of Total IgA and IgA TTG. Serum IgG TTG was measured in cases with reported values of Total IgA below the lowest normal limits. Moreover, endoscopic biopsy of the small intestine was also performed for patients with positive serology.Of all the 101 studied participants, only four individuals (3.96 %) had positive test for IgA TTG (potential celiac disease). one of these patients refused to do endoscopy and endoscopic small intestine biopsy underwent for 3 patients. Two of them had normal pathology and one of them(0.99 %) was confirmed for celiac disease.The frequency of celiac disease in children with chronic constipation is slightly higher than general population but without significant difference(0.99% VS 0.6%; p=0.64). So the screening serologic test for celiac disease is not recommended in children with chronic constipation.

The diagnosis of Celiac Disease (CD) relies on the concordance of pathological, serological, genetic and clinical features. For this reason, the diagnosis of CD is often a challenge. Seronegative celiac disease (SNCD) is defined by the negativity of anti-tissue transglutaminase antibodies in the presence of a positive histology on duodenal biopsy samples, i.e. inflammatory infiltrate of intra-epithelial lymphocytes (IELs > 25/100 enterocytes), mild villous atrophy and uneven brush border associated to human leukocyte antigen (HLA) haplotype DQ2 and/or DQ8.SNCD is characterized by mucosal deposits of tissue transglutaminase (tTG)/anti-tTG immuno-complexes. These may counteract the passage of anti-tTG into the bloodstream, thus explaining seronegativity. Another reason for seronegativity may be found in an incomplete maturation of plasma cells with a consequent failure of antibodies production. This condition often characterizes immunoglobulin deficiencies, and, indeed, SNCD is common in subjects with immunoglobulin deficiencies.The management of SNCD still remains debated. The treatment option for SNCD may be represented by gluten free diet (GFD), but the usefulness and appropriateness of prescribing GFD are controversial. Some evidences support its use only in SNCD subjects showing CD clear clinical picture and compatible HLA status. The choice of GFD administration could be linked to an investigation able to diagnose SNCD in no doubt even if a reliable test is not currently available. On these bases, a test helping the diagnosis of SNCD is justifiable and desirable.